Lung Cancer
November 19
7 min read
Patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations and MET alterations whose disease progressed on osimertinib experienced statistically significant benefits in progression-free survival and overall survival from the addition of the MET tyrosine kinase inhibitor savolitinib to osimertinib vs platinum/pemetrexed in subsequent lines of treatment in the phase III SAFFRON trial.